A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Completed · Phase 3 · Has a placebo group

Conditions studied: Respiratory Tract Infection

In brief

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

Key facts

Study ID
NCT04424316
Run by
Pfizer
People needed
14727
Starts
2020-06-17
Expected to finish
2023-10-27
Last updated by the study team
2025-02-11

Who can join

Age: any, up to 49. Sex: female. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.